Abstract
Individualized remedy for patients is a middle objective of today’s clinical
approach and the need of our society. Many elements, starting from genes to proteins,
all stay unknown for their unique roles in human physiology. The accurate prognosis,
monitoring, and remedy of various problems require dependable biomarkers, for the
development of correct healing interventions. Precision medicine within the treatment
of Fibromyalgia Syndrome (FMS) has attracted a whole lot of attention, particularly
with the gene discovery pushing toward more modern know-how of the biology of
disorders. Genome-huge association research has proven that in fibromyalgia
pathogenesis, genetic factors are accountable for as much as 50% of the sickness
susceptibility. Candidate genes determined to be associated with fibromyalgia are
SLC64A4, TRPV2, MYT1L, and NRXN3. Fibromyalgia is an extensive
musculoskeletal pain disorder followed by fatigue, sleep, memory, and mood troubles.
Fibromyalgia syndrome (FMS) exacerbates painful sensations by altering the way the
brain and spinal cord process both painful and non-painful signals. While some
targeted treatments have shown promise in improving the condition of FMS patients in
the short term, there is an opportunity to delve deeper into the mechanisms at play.
With the aid of animal models, we can further explore the intricate interplay between
the brain and the spinal cord, identifying specific genes, loci, and potential failures
within the spinal cord that contribute to FMS.
Additionally, FMS has been linked to biogenic amine depletion and mitochondrial
dysfunction. These factors represent crucial avenues for investigation. This chapter
aims to spotlight the significant advancements in technology that facilitate personalized
or precision medicine approaches for FMS. Since FMS is closely tied to the
functioning of the brain and spinal cord, research using animal models offers a
promising avenue, as conducting experiments on patients presents logistical challenges.